Cell-free DNA analysis for noninvasive examination of trisomy

New England Journal of Medicine

Volumn 372, Issue 17, 2015, Pages 1589-1597

  Norton, Mary E ^a   Jacobsson, Bo ^e   Swamy, Geeta K ^f   Laurent, Louise C ^b   Ranzini, Angela C ^g   Brar, Herb ^c   Tomlinson, Mark W ^h   Pereira, Leonardo ⁱ   Spitz, Jean L ^j   Hollemon, Desiree ^d   Cuckle, Howard ^k   Musci, Thomas J ^d   Wapner, Ronald J ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Riverside Perinatal Diagnostic Center   (United States)

^d Ariosa Diagnostics   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f DUKE UNIVERSITY   (United States)

^g SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^h Northwest Perinatal Center   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j Perinatal Quality Foundation   (United States)

^k Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; ANEUPLOIDY; AREA UNDER THE CURVE; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; DNA DETERMINATION; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INVASIVE PROCEDURE; NUCHAL TRANSLUCENCY MEASUREMENT; PHYSICAL EXAMINATION; PREGNANT WOMAN; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRISOMY 13; TRISOMY 18; TRISOMY 21; ADOLESCENT; BLOOD; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONGENITAL MALFORMATION; FETUS; GENETICS; LABORATORY DIAGNOSIS; MIDDLE AGED; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHROMOSOME ABERRATIONS; DNA; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; FETUS; HUMANS; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84926492837     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1407349     Document Type: Article

References (26)

1. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015;45:249-66.
2. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207(5):374.e1-374.e6.
3. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370:799-808.
4. Dan S, Wang W, Ren J, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 2012;32:1225-32.
5. th ed. Baltimore: Johns Hopkins University Press, 2010:771-818.
6. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206(4):319.e1-319.e9.
7. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207(2):137.e1-137.e8.
8. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32:3-9.
9. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
10. Liddell D. Practical tests of 2 x 2 contingency tables. J R Stat Soc D 1976;25:295-304.
11. Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics 2000;56:345-51.
12. Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-13.
13. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
14. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206(4):322.e1-322.e5.
15. Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn 2013;33:662-6.
16. Rava RP, Srinivasan A, Sehnert AJ, Bianchi DW. Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. Clin Chem 2014;60:243-50.
17. Pergament E, Cuckle H, Zimmermann B, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol 2014;124:210-8.
18. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome - a cost sensitivity analysis. Prenat Diagn 2013;33:636-42.
19. Samango-Sprouse C, Banjevic M, RyanA, et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn 2013;33:643-9.
20. Nicolaides KH, Musci TJ, Struble CA, Syngelaki A, Gil MM. Assessment of fetal sex chromosome aneuploidy using directed cell-free DNA analysis. Fetal Diagn Ther 2014;35:1-6.
21. Petersen OB, Vogel I, Ekelund C, Hyett J, Tabor A. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. Ultrasound Obstet Gynecol 2014;43:265-71.
22. Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH. Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities. Fetal Diagn Ther 2014;35:174-84.
23. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33:622-9.
24. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-4.
25. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15:395-8.
26. Wilson KL, Czerwinski JL, Hoskovec JM, et al. NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. J Genet Couns 2013;22:4-15.